glp-1 and prostate cancer Agonists: Dual Benefits for Diabetes GLP1 Receptor Agonism Alters Growth

Personalization through genetics removes guessworkyour dose may need to go up, but your price won'tensuring you receive the most effective medication for your body's unique biology

Karthik Achari, founder and CEO of PepMD, said that the strongest argument against GLP-1s being PEDs is the fact that the drugs would likely harm athletic performance more than they would help

Consideration: Injections require clinical administration, which provides monitoring and customization opportunities but also demands regular appointments

10.1186/s13023014-01308 96

van Vliet S, Koh HE, Patterson BW, Yoshino M, LaForest R, Gropler RJ, et al